Head-to-head · WeighScore
Sumbare Wellness vs Voxy
The verdict
Voxy takes it — 62.4/100 to 61.9/100, but only just.
Voxy grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Voxy is a Scottsdale, Arizona telehealth practice offering compounded semaglutide and tirzepatide alongside NAD+ and sermorelin. Sumbare Wellness is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Sumbare Wellness | Voxy |
|---|---|---|
| WeighScore | 61.9/100 | 62.4/100 |
| Grade | C | C |
| Scorecard rank | #281 | #272 |
| Semaglutide | $199/mo (all doses, compounded) | $179/mo (compounded) |
| Tirzepatide | $199/mo (all doses, compounded) | $299/mo (compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #281 · C
Strengths
- One flat $199/month price covering medication, provider review and shipping, with no consultation fee and no dose-change surcharge
- Charges nothing if a provider does not approve you
- Offers a deliberate low-dose microdosing protocol aimed at body composition, which most competitors do not break out
- Publishes a named legal entity, a US mailing address and a working phone number
- Pre-screening quiz is short and asks your goal before any medical question
Where it loses points
- Cancellation terms contradict three ways: the homepage says cancel anytime, the Terms say 48 hours notice, the FAQ says 30 days
- Availability is unclear: the homepage counter reads 3 states while the treatment pages say telehealth nationwide, and no state list is published
- Its chart cites placebo-controlled trials of compounded semaglutide and tirzepatide, which do not exist; those trials studied the branded drugs
- No compounding pharmacy is named, and neither 503A nor 503B appears anywhere on the site
- Any returned prescription is charged a $35 disposal fee, and prescription orders cannot be cancelled at all after 24 hours
Graded #272 · C
Strengths
- Names both its compounding pharmacy (VialsRX, Houston TX) and its prescribing medical group (Arora Health & Aesthetics) — most name neither
- Publishes the full price ladder for both drugs across 1-, 3-, 6- and 12-month terms before you start the assessment
- One price covers the provider visit, medication, injection supplies, shipping and monthly check-ins — no separate membership fee
- True month-to-month option at $179 semaglutide / $299 tirzepatide with no commitment required
- Free assessment with no charge to see if you qualify, and no labs required to start
Where it loses points
- No terms of service anywhere on the site — /terms, /terms-of-service and /terms-of-use all return 404
- No refund policy published; the only stated commitment language is 'cancel anytime'
- Advertised 'Starting at $129/mo' is the 12-month prepay rate — month-to-month is $179 semaglutide and $299 tirzepatide
- No public list of states served; availability depends on where affiliated providers are licensed
- The prescribing nurse practitioner is not named — 'provider details available during your consultation'
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.